EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Clinical Assessment of the Drug Interaction Potential of the Psychotropic Natural Product Kratom

Rakshit S Tanna, James T Nguyen iD, Deena L Hadi, Matthew E Layton, John R White, Nadja B Cech, Nicholas H Oberlies iD, Allan E Rettie, Kenneth E Thummel, Mary F Paine iD

Clinical Pharmacology & Therapeutics · 2023-06 · 113 (6) · 1315-1325

DOI: 10.1002/cpt.2891 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 28.03.2023. Verfasst von Rakshit S Tanna und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington, USA. Hauptthemen laut MEDLINE: Mitragyna, Biological Products. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCCIH NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oral formulations prepared from the leaves of the kratom ( Mitragyna speciosa ) plant are increasingly used for their opioid‐like effects to self‐manage opioid withdrawal and pain. Calls to US poison centers involving kratom exposures increased >50‐fold from 2011–2017, one‐third of which reported concomitant use of kratom with drugs of abuse. Many of these drugs are eliminated primarily via cytochrome P450 (CYP) 3A and CYP2D6, raising concerns for potential adverse pharmacokinetic kratom‐drug interactions. The impact of a single low dose of kratom tea (2 g) on the pharmacokinetics of the CYP3A probe midazolam (2.5 mg) and CYP2D6 probe dextromethorphan (30 mg) were assessed in 12 healthy adult participants after oral administration. Kratom showed no effect on dextromethorphan area under the plasma concentration time‐curve (AUC) and maximum concentration ( C max ; geometric mean ratio (90% confidence interval) 0.99 (0.83–1.19) and 0.96 (0.78–1.19), respectively) but a modest increase in midazolam AUC and C max (1.39 (1.23–1.57) and 1.50 (1.32–1.70), respectively). Lack of change in midazolam half‐life (1.07 (0.98–1.17)) suggested that kratom primarily inhibited intestinal CYP3A. This inference was further supported by a physiologically based pharmacokinetic drug interaction model using the abundant alkaloid mitragynine, a relatively potent CYP3A time‐dependent inhibitor in vitro ( K I , ~4 μM; k inact , ~0.07 min −1 ). This work is the first to clinically evaluate the pharmacokinetic drug interaction potential of kratom. Co‐consuming kratom with certain drugs extensively metabolized by CYP3A may precipitate serious interactions. These data fill critical knowledge gaps about the safe use of this increasingly popular natural product, thereby addressing ongoing public health concerns.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MitragynaBiological ProductsAdultHumansAnalgesics, OpioidMidazolamCytochrome P-450 CYP2D6Cytochrome P-450 CYP3ADextromethorphanPsychotropic DrugsDrug InteractionsCytochrome P-450 CYP3A Inhibitors

Substanzen

Analgesics, OpioidMidazolamBiological ProductsCytochrome P-450 CYP2D6Cytochrome P-450 CYP3ADextromethorphanPsychotropic DrugsCytochrome P-450 CYP3A Inhibitors

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington, USA.
  • Center of Excellence for Natural Product Drug Interaction Research, Spokane, Washington, USA.
  • Elson S. Floyd College of Medicine, Washington State University, Spokane, Washington, USA.
  • Department of Pharmacotherapy, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington, USA.
  • Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, North Carolina, USA.
  • Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle, Washington, USA.

ORCID-Profile: James T Nguyen, Nicholas H Oberlies, Mary F Paine

Förderung

  • NCCIH NIH HHS

Zitieren

APA

Tanna, R. S., Nguyen, J. T., Hadi, D. L., Layton, M. E., White, J. R., Cech, N. B., Oberlies, N. H., Rettie, A. E., Thummel, K. E., & Paine, M. F. (2023). Clinical Assessment of the Drug Interaction Potential of the Psychotropic Natural Product Kratom. Clinical Pharmacology & Therapeutics, 113(6), 1315-1325. https://doi.org/10.1002/cpt.2891

Vancouver

Tanna RS, Nguyen JT, Hadi DL, Layton ME, White JR, Cech NB, et al. Clinical Assessment of the Drug Interaction Potential of the Psychotropic Natural Product Kratom. Clinical Pharmacology & Therapeutics. 2023;113(6):1315-1325. doi:10.1002/cpt.2891

BibTeX
@article{Tanna2023,
  author = {Tanna, Rakshit S and Nguyen, James T and Hadi, Deena L and Layton, Matthew E and White, John R and Cech, Nadja B and Oberlies, Nicholas H and Rettie, Allan E and Thummel, Kenneth E and Paine, Mary F},
  title = {Clinical Assessment of the Drug Interaction Potential of the Psychotropic Natural Product Kratom},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2023},
  volume = {113},
  number = {6},
  pages = {1315--1325},
  doi = {10.1002/cpt.2891}
}
Kostenlos starten →